Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 25, 2022 | Series B | $35M | 2 | — | — | Detail |
May 24, 2021 | Series B | — | 1 | — | — | Detail |
May 3, 2021 | Series A | $32M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Korify Capital | — | Series B |
Gaingels | — | Series B |
NJF Capital | — | Series B |